Literature DB >> 23955572

Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapy.

F Ducray1, G Kaloshi, C Houillier, A Idbaih, B Ribba, D Psimaras, Y Marie, B Boisselier, A Alentorn, L Dainese, S Navarro, K Mokhtari, M Sanson, K Hoang-Xuan, Jean-Yves Delattre.   

Abstract

The aim of the present study was to evaluate the impact of first-line radiotherapy on low-grade gliomas (LGGs) growth kinetics. The mean tumor diameter (MTD) of 39 LGGs was retrospectively measured on serial magnetic resonance images before (n = 16) and after radiotherapy onset (n = 39). After radiotherapy, a decrease of the MTD was observed in 37 patients. Median duration of the MTD decrease was 1.9 years (range 0-8.1 years). According to RANO criteria, the rates of partial and minor responses were 15 and 28 % at the first evaluation after radiotherapy and 36 and 34 % at the time of maximal MTD decrease. The presence of a 1p19q codeletion and the absence of p53 expression were associated with longer durations of MTD decrease (5.3 vs 1 years, p = 0.02 and 2.4 vs 1.8 years, p = 0.05, respectively) while no association was observed between IDH1-R132H expression and duration of MTD decrease. In most patients, MTD decrease after radiotherapy occurred in two phases: an initial phase of rapid MTD decrease followed by a second phase of slower MTD decrease. Patients with a high rate of MTD decrease during the initial phase (>7 mm/year) had both a shorter duration of response (1.9 vs 5.3 years, p = 0.003) and a shorter overall survival (5.5 vs 11.6 years, p = 0.0004). LGGs commonly display a prolonged and ongoing volume decrease after radiotherapy. However, patients who respond rapidly should be carefully monitored because they are at a higher risk of rapid progression.

Entities:  

Mesh:

Year:  2013        PMID: 23955572     DOI: 10.1007/s11060-013-1224-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression.

Authors:  Virginie Desestret; Pietro Ciccarino; François Ducray; Emmanuelle Crinière; Blandine Boisselier; Marianne Labussière; Marc Polivka; Ahmed Idbaih; Gentian Kaloshi; Andreas von Deimling; Khe Hoang-Xuan; Jean-Yves Delattre; Karima Mokhtari; Marc Sanson
Journal:  J Neurooncol       Date:  2011-04-24       Impact factor: 4.130

2.  Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas.

Authors:  Johan Pallud; Jean-François Llitjos; Frédéric Dhermain; Pascale Varlet; Edouard Dezamis; Bertrand Devaux; Raphaëlle Souillard-Scémama; Nader Sanai; Maria Koziak; Philippe Page; Michel Schlienger; Catherine Daumas-Duport; Jean-François Meder; Catherine Oppenheim; François-Xavier Roux
Journal:  Neuro Oncol       Date:  2012-03-13       Impact factor: 12.300

3.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

Authors:  Gregory Cairncross; Brian Berkey; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperierre; Minesh Mehta; Walter Curran
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

4.  Continuous growth of mean tumor diameter in a subset of grade II gliomas.

Authors:  Emmanuel Mandonnet; Jean-Yves Delattre; Marie-Laure Tanguy; Kristin R Swanson; Antoine F Carpentier; Hugues Duffau; Philippe Cornu; Rémy Van Effenterre; Ellsworth C Alvord; Laurent Capelle
Journal:  Ann Neurol       Date:  2003-04       Impact factor: 10.422

5.  A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy.

Authors:  Benjamin Ribba; Gentian Kaloshi; Mathieu Peyre; Damien Ricard; Vincent Calvez; Michel Tod; Branka Cajavec-Bernard; Ahmed Idbaih; Dimitri Psimaras; Linda Dainese; Johan Pallud; Stéphanie Cartalat-Carel; Jean-Yves Delattre; Jérôme Honnorat; Emmanuel Grenier; François Ducray
Journal:  Clin Cancer Res       Date:  2012-07-03       Impact factor: 12.531

Review 6.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

Authors:  M J van den Bent; J S Wefel; D Schiff; M J B Taphoorn; K Jaeckle; L Junck; T Armstrong; A Choucair; A D Waldman; T Gorlia; M Chamberlain; B G Baumert; M A Vogelbaum; D R Macdonald; D A Reardon; P Y Wen; S M Chang; A H Jacobs
Journal:  Lancet Oncol       Date:  2011-04-05       Impact factor: 41.316

7.  Low grade glioma: a measuring radiographic response to radiotherapy.

Authors:  G Bauman; P Pahapill; D Macdonald; B Fisher; C Leighton; G Cairncross
Journal:  Can J Neurol Sci       Date:  1999-02       Impact factor: 2.104

8.  Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma.

Authors:  L D Lunsford; S Somaza; D Kondziolka; J C Flickinger
Journal:  J Neurosurg       Date:  1995-04       Impact factor: 5.115

9.  Dynamic history of low-grade gliomas before and after temozolomide treatment.

Authors:  Damien Ricard; Gentian Kaloshi; Alexandra Amiel-Benouaich; Julie Lejeune; Yannick Marie; Emmanuel Mandonnet; Michèle Kujas; Karima Mokhtari; Sophie Taillibert; Florence Laigle-Donadey; Antoine F Carpentier; Antonio Omuro; Laurent Capelle; Hugues Duffau; Philippe Cornu; Rémy Guillevin; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

10.  Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Authors:  G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

View more
  2 in total

1.  Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.

Authors:  C Izquierdo; A Alentorn; A Idbaih; M Simó; G Kaloshi; D Ricard; M Barritault; D Meyronet; J Bruna; J Honnorat; J Y Delattre; F Ducray
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

2.  Initial PCV Chemotherapy Followed by Radiotherapy Is Associated With a Prolonged Response But Late Neurotoxicity in 20 Diffuse Low-Grade Glioma Patients.

Authors:  Marie Blonski; Tiphaine Obara; Cyril Brzenczek; Celso Pouget; Céline Dillier; Mylène Meyer; Laura Lavigne; Natacha Forthoffer; Aurélie Broussois; Guillaume Gauchotte; Marie-Hélène Baron; Fabien Rech; Sophie Mézières; Yann Gaudeau; Antoine Verger; Guillaume Vogin; René Anxionnat; Jean-Marie Moureaux; Luc Taillandier
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.